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Objective: With little research about the disease progression and its variants from asymptomatic individuals to 
patients suffering from type 2 respiratory failure, it has been a challenge to diagnose the affected individuals and 
control its spread. Different initial researches indicated the presence of sudden anosmia and dysgeusia in 
asymptomatic or mild symptomatic carriers. Hence the purpose of my research was to find out the frequency of 
these symptoms in COVID-19 positive patients. 
Materials and Methods:  This is a retrospective study of 157 patients who were tested positive with COVID-19 
between March and September 1, 2020. Because of restrictions on visits to clinics and hospitals and increased risk 
of exposure during the epidemic, patients were not examined. Data was collected through Google forms and 
telephonic interviews of patients who suffered from COVID-19 in the past. 
Results: The data were analyzed using SPSS version 23. According to our result, of all the patients who suffered 
from COVID-19 59.2% of patients presented with sudden onset anosmia, and 55.3% presented with sudden 
hypogeusia without any previous history of such symptoms. 
Conclusion: The purpose of my research was to conclude the frequency of symptoms of sudden onset anosmia 
and dysgeusia in COVID-19 patients in Pakistan. This will facilitate timely screening and thus isolation of affected 
individuals, thus decreasing the spread and lowering the curve. As proven, in addition to fever and sudden onset 
dry cough, isolated sudden onset anosmia (ISOA) should be considered one of the presenting complaints. 
The study included 90 patients presenting with clinical symptoms of COVID-19 but with negative RT-PCR. All 
patients underwent chest computed tomography (CT). Patients having non-COVID-19 HRCT features with 
negative RT-PCR were excluded from the study. 
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Introduction 
 
The coronavirus disease is a new pandemic, first 
arising from Wuhan, China. It is caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-
COV-2). It was considered a pandemic by World 
Health Organization on 30th January 2020. Ever since it 
has affected millions of populations. 
The first case of Pakistan was confirmed on 26th Feb 
2020. The government announced a worldwide 
lockdown on 24th March 2020. After a lockdown of 1 
and a half months, it was lifted because of the 
economic crisis. The number of COVID patients is 
increasing ever since. Being a third-world country it is 
difficult to practice successful lockdown to practice 
social distancing and strict hygiene measures. Thus 
timely diagnosis and timely isolation are key to lower 
the spread of this infection. 
With little research about the disease progression and 
its variants from asymptomatic individuals to patients 
suffering from type 2 respiratory failure, it has been a 
challenge to diagnose the affected individuals and 
control its spread. Different initial researches indicated 
the presence of sudden anosmia and dysgeusia in 
asymptomatic or mild symptomatic carriers.1 It is 
thought to be caused by indirect neural pathway 
involvement (involvement of supporting neural 
tissues) instead of secondary anosmia caused by nasal 
congestion and blockage.2 
We aimed to describe the prevalence of anosmia in our 
population with confirmed COVID-19. 
 
Materials and Methods 
 
This is a retrospective observational study of 157 
patients who were tested positive with COVID -19 
between March and September 1, 2020. The diagnosis 
was mostly confirmed by PCR on respiratory samples, 
mainly nasopharyngeal or oropharyngeal swabs. Few 
cases were reported after positive Blood IgG. Because 
of restrictions on visits to clinics and hospitals and 
increased risk of exposure during the epidemic, 
patients were not examined. Data was collected 
through Google forms and telephonic interviews of 
patients who suffered from COVID-19 in the past. 
Patients’ contacts were taken from government 
hospital data after taking all the ethical considerations. 
Only patients who complained of new-onset anosmia 
were considered in the study to rule out chronic causes 
of anosmia. Smell and taste testing were also not 
performed due to security limitations in the COVID-19 
pandemic. Usual descriptive statistics were used. 
Categorical variables were expressed as numbers, 
percentages, or mean. Continuous variables were 




The data was analyzed using SPSS version 23. The age 
of the subjects ranged from 9 years to 72 years with a 
mean of 37.4 ± 13.9 years. Majority of the subjects were 
aged between 30-60 years (n = 81, 53.3%), followed by 
60 (39.5%) patients aged <30 years and 11 (7.2%) 
patients aged >60 years. There were 80 (52.6%) male 
and 72 (47.4%) female subjects with a male to female 
ratio of 1:1.1.  
Table 1:  
Age Frequency Percentage 
< 30 years 60 39.5% 
30-60 years 81 53.3% 
> 60 years 11 7.2% 
Table 2: 
Gender Frequency Percentage 
Male 80 52.6% 
Female 72 47.4% 
According to our study, 90 patients (59.2%) patients 
suffered from loss of smell, and the median age of 
recovery was 8 days. 84 patients (55.3%) patients 
suffered from loss of taste and the median age of 
recovery was 10 days. 
 
Figure 1: Percentage of Symptoms   
My data also included the severity of symptoms 
ranging from no symptoms to severe symptoms 
requiring ICU admission. Deceased patients were not 
included in the study. Patients with mild symptoms 
(high-grade fever, severe cough, or severe body aches) 
were 62% (n=62) and patients with severe symptoms 
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(severe respiratory complication requiring ICU 
admission) were 13.2% (n=20) 
 
 




In recent months, since the beginning of novel 
coronavirus, it has been seen that COVID causes loss 
of sense of smell and taste in affected patients, and in 
many, these are the only associated symptoms. 
Anosmia and hypogeusia were initially not taken as 
key symptoms in China, reporting only 5% of COVID-
19 patients to be affected with this symptom,⁸ but in 
Europe, the Middle East, and North America showed 
higher prevalence. 
According to our study, 90 patients (59.2%) patients 
suffered from loss of smell, and the median age of 
recovery was 8 days. 84 patients (55.3%) patients 
suffered from loss of taste and the median age of 
recovery was 10 days. 
Comparing my results with other studies, in research 
conducted in Italy, 73.6% reported complaints of 
chemosensory dysfunction during their COVID 
infection. The analysis of the patient confirmed that 
ageusia and anosmia are early symptoms in 
COVID‐19, generally occurs within the first 5 days of 
the clinical onset.3 
In a research published in the official journal of the 
American Academy of Otolaryngology-Head and 
Neck Surgery, conducted in Iran, it was noted that 
many COVID patients first presented with sudden 
symptoms of anosmia, hyposmia, and hypogeusia and 
a high proportion of seriously ill COVID patients had 
initial complain of anosmia alone.4 
In another research conducted in the USA, it was 
noted that in 237 patients of COVID-19, 73% had 
complained of anosmia before the diagnosis.5 In a 
research conducted from 1st March 2020 to 17th March 
2020 in France, 47% with a confirmed diagnosis of 
corona reported anosmia and 85% had dysgeusia.6 
According to the above-mentioned studies, there is a 
huge variation in the key symptoms in different 
countries ranging from 40% to almost 80% of anosmia 
and ageusia in COVID-positive patients. The purpose 
of my research was to conclude the frequency of 
symptoms of sudden onset anosmia and dysgeusia in 
COVID-19 patients in Pakistan. This will facilitate 
timely screening and thus isolation of affected 
individuals.7 It will help in the isolation of affected 
non-symptomatic to mild symptomatic patients. In 
absence of PCR testing, anosmia can serve as a free 
and specific diagnostic tool for developing countries 




Sudden onset anosmia and ageusia are key features of 
SARS-COVID-19 present in half of the population 
studied and were often associated with dysgeusia. In 
this time of rapidly spreading disease, anosmia and 
ageusia can be used as tools to identify the carriers and 
mildly symptomatic patients of the corona virus. This 
will help in decreasing the load of pathologists and 
will facilitate the rapid isolation of patients. 
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